EUVIMEDEUVIMED entdecken
Crossref

HBV PreS Variants Significantly Decrease in Liver Tissues After 104 Weeks of Antiviral Therapy With Nucleos(t)ide Analogues

Haohui Deng iD, Xiaoting Liang, Jiuxiang Qiu, Shuyuan Dang, Quxia Zhong, Zhilan Li, Jianying Xu, Minheng Wu, Jingzhang Wu, Huiyuan Liu, Min Xu, Hongbo Gao

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Haohui Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Fifth People's Hospital of Shunde District, Foshan City (Longjiang Hospital of Shunde District, Foshan City), F…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, Liver, Hepatitis B, Chronic. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Medical Scientific Research Foundation of Guangdong Province, China, Medical Research Project of Health Bureau, Foshan City, Guangzhou Science and Technology Plan Project: Municipal, School (Institute) and Enterprise Combined Funding Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nucleos(t)ide analogues (NAs) are widely used in patients infected with hepatitis B virus (HBV). However, limited data are available on the changes of the HBV variants at 2 years (104 weeks, w) after therapy, largely due to the difficulty in detecting the viral genome in peripheral blood. In our study, fifteen HBV‐infected patients (HBV e antigen positive) were enrolled, liver biopsy was performed at baseline and 104 w to evaluate liver fibrosis, and the clinically significant HBV variants related to hepatocellular carcinoma (HCC) and viral quasispecies diversity were also analyzed. PreS deletions were found in eight patients (53.3%) at baseline. All the eight patients showed a decrease in preS deletions after antiviral therapy ( p < 0.05). Moreover, all the eight patients with the preS2 start codon mutations/deletions at baseline were decreased after NAs treatment. BCP/preC mutations did not significantly change among the patients, including the eight patients achieved HBeAg seroconversion (all p > 0.05). HBV quasispecies diversity did not show significant differences, and no NAs‐related drug resistance mutations were found in the eight patients with low‐level viremia. The reduction of HBV preS variants may represent one of the important mechanisms by which NAs therapy lowers the risk of progression to HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B virusLiverHepatitis B, ChronicHepatitis B Surface AntigensNucleosidesProtein PrecursorsHumansFemaleMaleMiddle AgedAdultBiopsyGenetic VariationCarcinoma, HepatocellularSequence DeletionDNA, ViralLiver CirrhosisLiver Neoplasms

Stichwörter der Autor:innen

antiviral therapyhepatitis B virusliver tissuenucleos(t)ide analoguesvariants

Substanzen

Antiviral AgentsHepatitis B Surface AntigensNucleosidesProtein Precursorspresurface protein 2, hepatitis B surface antigenDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Disease, The Fifth People's Hospital of Shunde District, Foshan City (Longjiang Hospital of Shunde District, Foshan City), Foshan, China.
  • Department of Hepatology Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Haohui Deng

Förderung

  • Medical Scientific Research Foundation of Guangdong Province, China
  • Medical Research Project of Health Bureau, Foshan City
  • Guangzhou Science and Technology Plan Project: Municipal, School (Institute) and Enterprise Combined Funding Project

Zitieren

APA

Deng, H., Liang, X., Qiu, J., Dang, S., Zhong, Q., Li, Z., Xu, J., Wu, M., Wu, J., Liu, H., Xu, M., & Gao, H. (2026). HBV PreS Variants Significantly Decrease in Liver Tissues After 104 Weeks of Antiviral Therapy With Nucleos(t)ide Analogues. Journal of Medical Virology. https://doi.org/10.1002/jmv.71189

Vancouver

Deng H, Liang X, Qiu J, Dang S, Zhong Q, Li Z, et al. HBV PreS Variants Significantly Decrease in Liver Tissues After 104 Weeks of Antiviral Therapy With Nucleos(t)ide Analogues. Journal of Medical Virology. 2026. doi:10.1002/jmv.71189

BibTeX
@article{Deng2026,
  author = {Deng, Haohui and Liang, Xiaoting and Qiu, Jiuxiang and Dang, Shuyuan and Zhong, Quxia and Li, Zhilan and Xu, Jianying and Wu, Minheng and Wu, Jingzhang and Liu, Huiyuan and Xu, Min and Gao, Hongbo},
  title = {HBV PreS Variants Significantly Decrease in Liver Tissues After 104 Weeks of Antiviral Therapy With Nucleos(t)ide Analogues},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71189}
}
Kostenlos starten →